Takeda sees new Rozerem tact pay off

Share this article:
The whimsical consumer campaign for Takeda's insomnia drug Rozerem has generated lots of buzz, but not the kind of recognition that generally leads to new patient starts. That may be changing.

While the original goal of the effort, by Chicago's Cramer-Krasselt and AbelsonTaylor, was to cut through the blizzard of Ambien and Lunesta ads, Takeda said it's evolving the campaign to drive trials of Rozerem.

The company says two new TV spots that debuted this year featuring the same offbeat cast of dream-inspired characters have prompted more patients to actually mention Rozerem by name when discussing treatment options with their physician.

“In the very beginning, you find yourself as being, in the mind of the consumer, ‘You're the product…with Abe Lincoln and the beaver,'” said Chris Benecchi, director of Rozerem marketing for Takeda Pharmaceuticals North America.

“Now ‘Rozerem' is coming through much more strongly,” Benecchi said.

Indeed, Takeda would like to see its entrant in the $3.9-billion prescription insomnia category step out from behind its marketing shadow. The company says momentum is on its side. US marketing partner TAP Pharmaceutical, whose reps joined forces with those of Takeda's US subsidiary in touting Rozerem to doctors, became “really integrated” earlier this year, Benecchi said. Stronger personal promotion efforts, combined with the two new DTC executions, helped Rozerem post its second straight quarter of modest growth.

First-quarter fiscal sales (April-June) doubled over the year-ago period to $30 million, Takeda said in a statement, followed by a sales jump of 78% or $26 million in the previous quarter.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...